



Sandra Sanders-van Wijk

Contact

Sandra Sanders-van Wijk

Publications (8)

Lanfear D, Li J, Brunner-La Rocca H, Kraus W, Sabbah H, Maeder M, Zeld N, Sanders-van Wijk S, Adams K, O'Connor C, Donahue M, Gui H, She R, Luzum J, Williams L. Polygenic Score for Beta-Blocker Survival Benefit in European Ancestry Patients with Reduced Ejection Fraction Heart Failure. *Circ Heart Fail* 2020

Stöhr R, Sanders-van Wijk S, Pfisterer M, Jeker U, Schuh A, Leibundgut G, Maeder M, Heine G, Brandenburg V, Brunner-La Rocca H. Limited role for fibroblast growth factor 23 in assessing prognosis in heart failure patients: data from the TIME-CHF trial. *Eur J Heart Fail* 2020

Davarzani N, Brunner-La Rocca H, Peeters R, Pfisterer M, Zaugg C, Rolny V, Block D, de Boer R, Suter T, Karel J, Smirnov E, Rickenbacher P, Maeder M, Sanders-van Wijk S, TIME-CHF Investigators. Novel concept to guide systolic heart failure medication by repeated biomarker testing—results from TIME-CHF in context of predictive, preventive, and personalized medicine. *EPMA J* 2018; 9:161-173.

Davarzani N, Peeters R, Rickenbacher P, Pfisterer M, Gutmann M, Leibundgut G, Maeder M, Karel J, Sanders-van Wijk S, Brunner-La Rocca H. N-Terminal Pro-B-Type Natriuretic Peptide-Guided Therapy in Chronic Heart Failure Reduces Repeated Hospitalizations—Results From TIME-CHF. *J Card Fail* 2017; 23:382-389.

Sanders-van Wijk S, Brunner-La Rocca H, Latini R, Rickli H, Tobler D, Tavazzi L, Gorini M, Rickenbacher P, Milani V, Masson S. Interaction of Galectin-3 Concentrations with the Treatment Effects of β -Blockers and RAS Blockade in Patients with Systolic Heart Failure: A Derivation-Validation Study from TIME-CHF and GISSI-HF. *Clin Chem* 2016; 62:605-16.

Zurek M, Brunner-La Rocca H, Pfisterer M, Jeker U, Handschin R, Abbühl H, Sanders-van Wijk S, Muzzarelli S, Rickli H, Maeder M, TIME-CHF Investigators. Differential Prognostic Impact of Resting Heart Rate in Older Compared to Younger Patients with Chronic Heart Failure - Insights from TIME-CHF. *J Card Fail* 2015

Sanders-van Wijk S, Brunner-La Rocca H, Pfisterer M, Peter M, Rickenbacher P, Erne P, Estlinbaum W, Rickli H, Nietlispach F, Maeder M, TIME-CHF Investigators. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF. *Circ Heart Fail* 2013; 7:131-9.

Sanders-van Wijk S, Brunner-La Rocca H, Pfisterer M, Peter M, Vuillomenet A, Rickenbacher P, Erne P, Estlinbaum W, Rickli H, van Asselt A, TIME-CHF Investigators. Cost-effectiveness of N-terminal pro-B-type natriuretic-guided therapy in elderly heart failure patients: results from TIME-CHF (Trial of Intensified versus Standard Medical Therapy in Elderly Patients with Congestive Heart Failure). *JACC Heart Fail* 2013; 1:64-71.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch